Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
55results about How to "Genetic diagnosis specific" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Application of CFAP20 gene in diagnosis of osteoporosis
InactiveCN107043811AGenetic diagnosis moreTimely genetic diagnosisPeptide librariesNucleotide librariesOsteoporosisDifferentially expressed genes
The invention discloses an application of a CFAP20 gene as a molecular marker in early diagnosis of osteoporosis. The invention researches the differential expression genes in patients with osteoporosis by using high flux sequencing and QPCR experiments. The research findings of the invention show that whether a subject suffers from osteoporosis can be judged through detecting the condition of CFAP20 gene expression in blood, and the detection method can be used for early diagnosis of osteoporosis and has the characteristics of timeliness and accuracy.
Owner:TAISHAN MEDICAL UNIV
Molecular marker for osteoporosis and application of marker
ActiveCN105132575AAchieve early diagnosisReduce mortalityOrganic active ingredientsMicrobiological testing/measurementBone tissueWestern blot
The invention discloses an LYPD3 gene and an expression product thereof both of which can serve as molecular markers for diagnosing osteoporosis. According to the LYPD3 and the expression product disclosed by the invention, a QPCR (quantitative polymerase chain reaction) experiment and a Western blot experiment provide that the LYPD3 gene has expression difference in blood or bone tissues of a normal person and an osteoporosis patient and can be used as an index for early diagnosis of the osteoporosis. In addition, the invention also discloses the LYPD3 gene and the expression product thereof both of which can serve as targets for diagnosing the osteoporosis and be used for guiding the research and development of novel medicaments.
Owner:GUAN BOJIAN BIOTECH CO LTD
PLAC1 (placenta-specific 1) genes serving as diagnosis target of osteoarthritis
ActiveCN105200150AAchieve early diagnosisReduce mortalityOrganic active ingredientsMicrobiological testing/measurementDisease riskSynovial Cell
The invention discloses PLAC1 (placenta-specific 1) genes which can serve as a molecular marker for early diagnosis of osteoarthritis. Expressions of the PLAC1 genes in synovial tissue of a normal person and a patient suffering from osteoarthritis prove to be different in terms of the transcriptional level and the protein level, and accordingly, the disease risk and the disease state of a subject can be judged according to the identified expression level of the PLAC1 genes. Additionally, experiments prove that interference to expression of the PLAC1 genes or inhibition on the function of PLAC protein can inhibit proliferation of synovial cells, and a new target is provided for development of medicines for treating osteoarthritis clinically.
Owner:BEIJING MEDINTELL BIOMED CO LTD
MTUSI gene serving as osterarthritis diagnosis target
ActiveCN105112550AAchieve early diagnosisReduce mortalityPeptide/protein ingredientsMicrobiological testing/measurementOsteoblastBone tissue
The invention discloses an osterarthritis diagnosis marker which refers to MTUSI gene and expression products thereof. According to gene chip and protein immunization tests, expressions of the MTUSI gene and expression products thereof are lowered in blood and bone tissue of osterarthritis patients as compared with those of the normal; thus, products for diagnosis of osterarthritis can be developed and can be applied to testing expression level of the MTUSI gene or expression products thereof. According to experiment in vitro, bone cell proliferation can be improved by over-expression of the MTUSI gene, and accordingly the MTUSI gene and the expression products thereof can be applied to development of medicines for treating osterarthritis.
Owner:QINGDAO MEDINTELL BIOMEDICAL CO LTD
Application of EPB41L4B gene in diagnosis and treatment of Parkinson disease
ActiveCN105331690AAchieve early diagnosisReduce mortalityOrganic active ingredientsNervous disorderDrugResearch result
The invention discloses application of an EPB41L4B gene in diagnosis and treatment of a Parkinson disease. It is proved by experiments that compared with a normal person, expression of the EPB41L4B gene in the blood of a Parkinson disease patient is up-regulated, and it is shown that whether a subject suffers from the Parkinson disease or not can be diagnosed according to the expression level of EPB41L4B in the blood. According to the research results of the application of the EPB41L4B gene in the diagnosis and treatment of the Parkinson disease, the EPB41L4B can further be used for preparing a drug for treating the Parkinson disease. According to the application of the EPB41L4B gene in the diagnosis and treatment of the Parkinson disease, the sensibility and the specificity of Parkinson disease diagnosis are greatly improved, and meanwhile a new target is provided for gene treatment of the Parkinson disease.
Owner:QINGDAO MEDINTELL BIOMEDICAL CO LTD
CERS2 (ceramide synthase 2) gene and its expression product serving as treatment target of osteoporosis
ActiveCN105200137AAchieve early diagnosisReduce mortalityMicrobiological testing/measurementSkeletal disorderOsteoblastTreatment targets
The invention discloses a CERS2 (ceramide synthase 2) gene and its expression product serving as a molecular marker for treating osteoporosis. Judgment may be given to whether a patient with osteoporosis or a treatment subject has the risk of suffering from osteoporosis, by detecting CERS2 gene and its expression product contents of bone tissues. The study on proliferation of osteoblasts cultured in vitro discovers that the expression inhibition of the CERS2 gene may promote the proliferation of the osteoblasts and that the proliferation of the osteoblasts may also be promoted by inhibiting the function of CERS2 proteins, and results of the study show that the CERS2 gene and its expression product are potential drug targets for treating osteoporosis.
Owner:QINGDAO MEDINTELL BIOMEDICAL CO LTD
Molecular marker for diagnosis and treatment of osteoporosis
ActiveCN105087821AAchieve early diagnosisReduce mortalityPeptide/protein ingredientsGenetic material ingredientsNormal peopleOsteoblast
The invention discloses a molecular marker for diagnosis and treatment of osteoporosis, wherein the marker for diagnosis and treatment of osteoporosis is KPNA3 gene and expression products thereof. The high-throughput sequencing and QPCR method show that the KPNA3 gene and expression products thereof have differences in expression in bone tissues between normal people and patients with osteoporosis, and according to the correlation between the expression differences, the KPNA3 gene and expression products thereof can be used for serving as the molecular marker for diagnosis and treatment of osteoporosis. In addition, in vivo experiments show that over-expression of the KPNA3 gene can promote the proliferation of bone cells, therefore the KPNA3 gene and the expression products thereof can also be used for development of drugs for treating osteoporosis.
Owner:QINGDAO MEDINTELL BIOMEDICAL CO LTD
Molecular marker for nasopharynx cancer diagnosis and treatment
ActiveCN105296656AAchieve early diagnosisReduce mortalityMicrobiological testing/measurementBiological material analysisWestern blotNasopharyngeal carcinoma
The invention discloses a molecular marker, namely an SMPD3 gene and an expression product thereof which are used for early diagnosis of nasopharynx cancer. QPCR and Western blot methods prove that the expressions of the SMPD3 gene in a nasopharynx cancer patient and a normal person are different, which can be used as an index for early diagnosis of nasopharynx cancer. In addition, the invention further discloses the expression product of the SMPD3 gene, and the expression product can be used as a therapeutic target of nasopharynx cancer for guiding the development of new medicines.
Owner:QINGDAO MEDINTELL BIOMEDICAL CO LTD
Diagnosis and treatment target of degenerative disc disease
ActiveCN105603085AAchieve early diagnosisReduce mortalityMicrobiological testing/measurementSkeletal disorderApoptosisTreatment targets
The invention discloses a diagnosis and treatment target TULP2 gene of a degenerative disc disease. Whether a subject has the degenerative disc disease or not can be judged or whether the subject has the risk of the degenerative disc disease or not can be diagnosed by detecting the content of TULP 2 gene and an expression product thereof in intervertebral disc tissues of the subject. In addition, the TULP2 gene is proved to be used as a drug target for treating the degenerative disc disease by researching growth, senility and apoptosis indexes of the in-vitro cultured nucleus pulposus cells.
Owner:QINGDAO MEDINTELL BIOMEDICAL CO LTD
Intervertebral disc degenerative change diagnosis and treatment marker
ActiveCN105400894ATimely genetic diagnosisGenetic diagnosis specificPeptide/protein ingredientsGenetic material ingredientsDegenerative changeIntervertebral disc
The invention discloses a gene TMED2 which can serve as a molecular marker for diagnosing the intervertebral disc degenerative change. Experiments prove that in comparison with a normal person, the expression quantity of the gene TMED2 in intervertebral disc degenerative change patients is large. The invention further discloses the gene TMED2 which can be used for preparing a drug for treating the intervertebral disc degenerative change. Apoptosis experiments prove that overexpression of the gene TMED2 can promote nucleus pulposus cell apoptosis. The research result provides a new intervertebral disc degenerative change clinic diagnosis method and provides a drug new target for treating the intervertebral disc degenerative change.
Owner:GUAN BOJIAN BIOTECH CO LTD
NUDT11 genes and expression products thereof serving as diagnosis targets of UL (uterine leiomyoma)
ActiveCN105648076AAchieve early diagnosisReduce mortalityOrganic active ingredientsGenetic material ingredientsResearch resultDrug
The invention discloses NUDT11 genes and expression products thereof serving as molecular markers for diagnosis of UL (uterine leiomyoma). Whether a subject suffers from UL can be judged and whether the subject has the risk of suffering from UL can be diagnosed by detecting the content of the NUDT11 genes and the expression products thereof in tissue. Researches on proliferation conditions of UL cells cultured in vitro show that expression inhibition of the NUDT11 genes can inhibit UL cell proliferation, proliferation of the UL cells can be inhibited by inhibiting the function of NUDT11 protein, and research results show that the NUDT11 genes and the expression products thereof are potential medicine targets for treatment of UL.
Owner:QINGDAO MEDINTELL BIOMEDICAL CO LTD
Gene combination for distinguishing non-invasive and invasive non-functional pituitary adenomas
ActiveCN112626207ASpecific diagnosisSensitive diagnosisMicrobiological testing/measurementMaterial analysisPhysiologyRHOB
The invention discloses a gene combination for distinguishing non-invasive and invasive non-functional pituitary adenomas. The gene combination consists of the following genes of INSM1, Jun, JunB, RHOU, RHOB, EZR, LLGL2, SNX33, SPIRE2, MLF1, HSPA2, CDKN1A, ERN1, NR2F2, GAS2, CDK6, SFRP1, EMILIN2, CD9 and SEMA7A. By detecting the expression level of the gene combination, the non-invasive and invasive non-functional pituitary adenomas can be distinguished.
Owner:PEKING UNION MEDICAL COLLEGE HOSPITAL CHINESE ACAD OF MEDICAL SCI +1
Application of ARHGAP26 gene to preparation of Parkinson diagnostic tool
InactiveCN108034714AAchieve early diagnosisReduce mortalityMicrobiological testing/measurementDisease diagnosisDiagnosis earlyPoor correlation
The invention discloses an ARHGAP26 gene capable of being taken as a molecular marker for early diagnosis of a Parkinson's disease. The invention discovers that significant differences exist in the expressions of the ARHGAP26 gene in blood of an average person and a patient with the Parkinson's disease by utilizing a gene chip and a QPCR method, that is, whether a subject suffers from the Parkinson's disease or not can be judged by detecting the expression situation of the ARHGAP26 gene in the blood. According to the correlation between the both, the invention develops a kit for diagnosing theParkinson's disease, the kit is used for the diagnosis of the Parkinson's disease by detecting the expression of the ARHGAP26 gene. The diagnostic kit developed by the invention can be used for earlydiagnosis on diseases and has a wide application prospect clinically.
Owner:QINGDAO MEDINTELL BIOMEDICAL CO LTD
Diagnosis and treatment markers for hysteromyoma
ActiveCN105506169AAchieve early diagnosisReduce mortalityOrganic active ingredientsMicrobiological testing/measurementCancer researchGene expression
The invention discloses GPSM2 genes which can be used as the molecular markers of the early diagnosis of hysteromyoma. Experiments prove that the GPSM2 gene expression in hysteromyoma tissue is increased evidently as compared with that of normal muscular layer tissue. RNA interference experiments prove that the GPSM2 can affect the proliferation of hysteromyoma cells. Medicine capable of inhibiting the GPSM2 gene expression can be developed, and clinical prevention and treatment of the hysteromyoma can be achieved.
Owner:QINGDAO MEDINTELL BIOMEDICAL CO LTD
Application of DACT2 gene in preparation of product for diagnosis and treatment of atrial fibrillation
ActiveCN110305950AAchieve early diagnosisReduce the probability of cardiovascular and cerebrovascular eventsMicrobiological testing/measurementDisease diagnosisMortality rateCardiac muscle
The invention discloses an application of DACT2 gene in preparation of a product for diagnosis and treatment of atrial fibrillation. The application finds for the first time that DACT2 gene expressionis associated with atrial fibrillation, by detecting the expression of DACT2 in the myocardial tissue of a subject, the subject can be judged whether the subject has atrial fibrillation or not, or whether the subject is at risk of having atrial fibrillation or not, so that a clinician can be instructed to provide the subject with a prophylactic scheme or a treatment scheme. The invention discovers a new molecular marker of atrial fibrillation-DACT2 gene, which is more timely, more specific and more sensitive than traditional detection methods, early diagnosis of atrial fibrillation can be achieved, and the mortality of atrial fibrillation is reduced.
Owner:THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
Application of C21orf62 gene in liver cancer diagnosis
InactiveCN105441571AAchieve early diagnosisReduce mortalityMicrobiological testing/measurementMaterial analysisTrue positive rateOncology
The invention discloses application of a C21orf62 gene in liver cancer diagnosis. The C21orf62 gene is in low expression in tissues of a liver cancer patient, through detecting the expression level of the C21orf62 gene, whether a patient suffers from liver cancer can be diagnosed, and through the application of the C21orf62 gene in liver cancer diagnosis, sensitivity and specificity of liver cancer diagnosis are greatly improved.
Owner:陈娟 +1
SENP3 gene and use of its expression product as diagnosis and treatment target for esophageal cancer
ActiveCN105861741AAchieve early diagnosisReduce mortalityMicrobiological testing/measurementAntineoplastic agentsTreatment targetsEsophageal cancer
The invention discloses SENP3 gene and use of its expression product as diagnosis and treatment target for esophageal cancer. Whether a subject has esophageal cancer can be determined or whether a subject is under risk of having esophageal cancer can be diagnosed by detecting the contents of SENP3 gene and its expression product in tissues. By studying proliferation of esophageal cancer cells cultured in vitro, it is discovered that expression inhibition for SENP3 gene may inhibit the proliferation of esophageal cancer cells, and by inhibiting functionality of SENP3 protein, it is also possible to inhibit the proliferation of esophageal cancer cells; results of this study show that SENP3 and its expression product are a potential drug target to treat esophageal cancer.
Owner:FOURTH HOSPITAL OF HEBEI MEDICAL UNIV
Application of product for detecting CALN1 gene expression in diagnosis of cholangiocarcinoma
ActiveCN105238872AAchieve early diagnosisReduce mortalityPeptide/protein ingredientsGenetic material ingredientsCALN1 geneLarge sample
The invention discloses CALN1 genes and an expression product thereof used as a molecular marker for the early diagnosis of cholangiocarcinoma. By utilizing RNA-sep screening and by virtue of large-sample RT-PCR verification, the abnormality of the CALN1 gene is associated to the occurrence and development of cholangiocarcinoma. According to a research result of the invention, a drug capable of improving the CALN1 gene expression level in cholangiocarcinoma tissues can be researched and developed, so that the cholangiocarcinoma can be clinically prevented and treated.
Owner:QINGDAO MEDINTELL BIOMEDICAL CO LTD
Application of TEX19 gene in diagnosis and treatment of biliary duct cancer
InactiveCN104894259AAchieve early diagnosisReduce mortalityOrganic active ingredientsGenetic material ingredientsDrugGene expression
The invention discloses a TEX19 gene and an expression product of the TEX19 gene serving as a molecular marker in early diagnosis of biliary duct cancer. In the invention, RNA-sep is used for screening, large-sample RT-PCR is used for verification, and TEX19 gene expression abnormity is related to generation and development of biliary duct cancer. According to the search achievements, a drug capable of inhibiting TEX19 gene expression in biliary duct tissue or inhibiting TEX19 gene from expressing product functions can be searched, thus realizing prevention and treatment of biliary duct cancer on clinic.
Owner:BEIJING MEDINTELL BIOMED CO LTD
Gene marker RGL4 of sepsis
InactiveCN106282355ATimely genetic diagnosisReduce mortalityMicrobiological testing/measurementBiological material analysisFhit geneDiagnosis early
The invention discloses a gene marker RGL4 of sepsis. The expression of the RGL4 gene in sepsis is up-regulated, so that early diagnosis can be provided for a patient with sepsis by detecting the expression level of the RGL4 gene, and early treatment and reduction of the case-fatality rate of the patient with sepsis are expected to be realized.
Owner:BEIJING MEDINTELL BIOMED CO LTD
Early diagnosis marker for hypertensive intracerebral hemorrhage
PendingCN110066871AAchieve early diagnosisReduce mortalityMicrobiological testing/measurementDisease diagnosisDiagnosis earlyPediatrics
The invention discloses application of a SETD6 gene for diagnosing hypertensive intracerebral hemorrhage. The SETD6 gene transcription level in blood of a patient suffering from hypertensive intracerebral hemorrhage has remarkable difference with that of a normal person, and according to the difference, the patient suffering from hypertensive intracerebral hemorrhage and the normal person can be distinguished. The invention further discloses a diagnosis product for hypertensive intracerebral hemorrhage. The diagnosis product can achieve diagnosis of hypertensive intracerebral hemorrhage by detecting the SETD6 gene in blood.
Owner:中国人民解放军联勤保障部队第九八0医院
Targets for diagnosis and treatment of degenerative disc disease
ActiveCN105603085BAchieve early diagnosisReduce mortalityMicrobiological testing/measurementSkeletal disorderTreatment targetsApoptosis
Owner:QINGDAO MEDINTELL BIOMEDICAL CO LTD
Application of genes VSIG10L as lung squamous carcinoma metastasis diagnosis and therapy marker
ActiveCN105648103ATimely genetic diagnosisGenetic diagnosis specificMicrobiological testing/measurementBiological material analysisLung squamous cell carcinomaLymphatic Spread
The invention discloses a gene marker. The gene marker VSIG10L can be used for judging whether metastasis of lung squamous carcinoma occurs or not or pre-judging lung squamous carcinoma metastasis risks. The gene marker VSIG10L further can be used for preparing medicines for inhibiting or preventing lung squamous carcinoma metastasis. The gene marker has the advantages that novel diagnosis methods can be provided for clinically diagnosing lung squamous carcinoma metastasis at molecular level, and novel medicine targets can be provided for gene therapy on lung squamous carcinoma metastasis.
Owner:QINGDAO MEDINTELL BIOMEDICAL CO LTD
LMNB2 gene and expression product thereof as diagnosing and treating target for nasopharyngeal carcinoma
ActiveCN105296622AAchieve early diagnosisReduce mortalityOrganic active ingredientsMicrobiological testing/measurementBone tissueNasopharyngeal carcinoma
The invention discloses a LMNB2 gene and an expression product thereof as a diagnosing and treating target for nasopharyngeal carcinoma. If a tested person is suffered from nasopharyngeal carcinoma or has the risk in suffering from nasopharyngeal carcinoma can be judged by detecting the content of LMNB2 gene and the expression product thereof in the bone tissue. According to the invention, the research on the multiplication condition of the nasopharyngeal carcinoma cells cultured in vitro proves that the expression of the LMNB2 gene can restrain the multiplication of the nasopharyngeal carcinoma cells, so that the multiplication of the nasopharyngeal carcinoma cells can be restrained by restraining the function of the LMNB2 protein. The result of the research proves that the LMNB2 gene and the expression product thereof are served as the potential drug targets for treating the nasopharyngeal carcinoma.
Owner:QINGDAO MEDINTELL BIOMEDICAL CO LTD
Diagnostic use of the nacc2 gene in blood
ActiveCN108220419BAchieve early diagnosisReduce mortalityMicrobiological testing/measurementBiological testingBiologyGene
Owner:QINGDAO MEDINTELL BIOMEDICAL CO LTD
A molecular marker for diagnosis and treatment of osteoporosis
ActiveCN105087821BAchieve early diagnosisReduce mortalityPeptide/protein ingredientsMicrobiological testing/measurementNormal peopleOsteoblast
Owner:QINGDAO MEDINTELL BIOMEDICAL CO LTD
plac1 gene as a target for diagnosis and treatment of osteoarthritis
ActiveCN105200150BAchieve early diagnosisReduce mortalityOrganic active ingredientsGenetic material ingredientsDisease riskSynovial Cell
The invention discloses PLAC1 (placenta-specific 1) genes which can serve as a molecular marker for early diagnosis of osteoarthritis. Expressions of the PLAC1 genes in synovial tissue of a normal person and a patient suffering from osteoarthritis prove to be different in terms of the transcriptional level and the protein level, and accordingly, the disease risk and the disease state of a subject can be judged according to the identified expression level of the PLAC1 genes. Additionally, experiments prove that interference to expression of the PLAC1 genes or inhibition on the function of PLAC protein can inhibit proliferation of synovial cells, and a new target is provided for development of medicines for treating osteoarthritis clinically.
Owner:BEIJING MEDINTELL BIOMED CO LTD
Use of vsig10l gene as a marker for the diagnosis and treatment of lung squamous cell carcinoma metastasis
ActiveCN105648103BTimely genetic diagnosisGenetic diagnosis specificMicrobiological testing/measurementBiological material analysisLung squamous cell carcinomaLymphatic Spread
Owner:QINGDAO MEDINTELL BIOMEDICAL CO LTD
Application of using PLCD4 gene as gastric adenocarcinoma transfer diagnosis marker
ActiveCN108048568AAchieve early diagnosisReduce mortalityMicrobiological testing/measurementPLCD4Molecular level
The invention discloses an application of using PLCD4 gene as a gastric adenocarcinoma transfer diagnosis marker. A gene chip is applied to screen a differential expression gene related to the gastricadenocarcinoma transfer, and QPCR verification is performed in a big sample; the experimental result shows that the PLCD4 can be used for judging if the gastric adenocarcinoma is transferred or the gastric adenocarcinoma transfer risk is judged in advance. The research result provides a new diagnosis method for clinical diagnosis of gastric adenocarcinoma transfer on a molecular level while provides a new drug target for the gene treatment of the gastric adenocarcinoma transfer.
Owner:GUIZHOU PROVINCIAL PEOPLES HOSPITAL
Senp3 gene and its expression products as targets for diagnosis and treatment of esophageal cancer
ActiveCN105861741BAchieve early diagnosisReduce mortalityMicrobiological testing/measurementAntineoplastic agentsTreatment targetsEsophageal cancer
Owner:FOURTH HOSPITAL OF HEBEI MEDICAL UNIV
Popular searches
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com